A study of a GLP-1 and GIP medicine, tirzepatide, in people with substance use disorders.

Recruiting now. Registry record last updated September 2, 2026.

Who can join: Adults 18 to 70, have substance use disorders.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor The University of Texas at DallasDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 40

What this study is for

Primary condition: Drug Discontinuation. Also studied in: Substance Use Disorders, Eating Behavior Changes, Tirzepatide.

Full scientific study title: Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation.

Who can join

Age18 to 70SexAny

Adults 18 to 70, have substance use disorders. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Aged 18-70 years.
Currently on tirzepatide.
Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.
Cognitively capable of understanding and signing informed consent.
Be proficient in English.

Key exclusion criteria

History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).
Diagnosis of Type 2 Diabetes.
Current diagnosis of an eating disorder.
Use of medications affecting weight other than tirzepatide.
Pregnancy or breastfeeding.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

Center for BrainHealth
Dallas, Texas
Samuel M Poelker-Wells, Master of Science972-883-3375sxp230129@utdallas.edu

Follow this trial

We email you if NCT07387796 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: October 2026. Expected completion: February 2029. Last updated on ClinicalTrials.gov: September 2, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.